メニュー
Meet the Program Commitee for 2023!
プログラム委員会
-
Claudia Ferreira • Scientific Programmes Specialist
DIA, Switzerland -
Sara Torgal, MPharm • Senior Manager, Scientific Programs
DIA, Switzerland -
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division
European Medicines Agency, Netherlands -
Karl Broich, DrMed • President
Federal Institute for Drugs and Medical Devices (BfArM), Germany -
Natasha Jarrett • Head Immunology, Infectious Disease, Ophthalmology, Neuroscience, Regulatory
F. Hoffmann-La Roche Ltd., Switzerland -
Indranil Bagchi, PhD, MSc • Global Head, Pricing & Market Access
GSK, United States -
Jan Geissler, MBA • Managing Director
Patvocates, Germany -
Magda Chlebus, MA • Executive Director, Science Policy & Regulatory Affairs
EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium -
Anja Schiel, PhD • Special Advisor, Lead Methodologist; Leader international HTA (iHTA) NoMA
Norwegian Medicines Agency (NoMA), Norway -
Ian Hudson • Senior Advisor, Integrated Development
Bill and Melinda Gates Foundation, United States -
Patrick Brady, PharmD • Head Regulatory Policy & Intelligence
Bayer AG / Research & Development, Pharmaceuticals, Germany -
Thomas Brookland, MSc • EU Data and AI Policy Lead
F. Hoffmann-La Roche Ltd, Switzerland -
Jesper Kjær, MS • Co-Chair, EMA/HMA Big Data Steering Group; Director of Data Analytics Centre
Danish Medicines Agency (DKMA), Denmark -
Thomas Schindler, PhD • Director Global Regulatory Affairs - Regulatory Operations
BioNTech SE, Germany -
Derek Johnston • QA Director, Regulatory Intelligence Office
Labcorp Drug Development, United Kingdom -
Lucia D'Apote, DrSc, RAC • Executive Director Global Regulatory and R&D Policy (ELMAC and JAPAC)
Amgen, Switzerland -
Ursula Busse, PhD, MBA • Head of Regulatory Affairs
Tigen Pharma SA, Switzerland -
Markus Goese • Head EU CMC Regulatory Policy
F. Hoffmann-La Roche Ltd, Switzerland -
Claudia Hey, DrSc, PharmD • Senior Director, Head Europe Global Regulatory & Scientific Policy
Merck Healthcare KGaA, Germany -
Laura Oliveira • Regulatory Affairs, Director
MSD Spain , Spain -
Bjorg Hunter, MSc • Director
Novo Nordisk, Denmark -
Tim Chesworth • Senior Director Regulatory Affairs
AstraZeneca, United Kingdom -
Francoise Sillan, MD • EU1 UK QPPV
Ipsen, France -
Phil Tregunno • Deputy Director - Patient Safety Monitoring
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom -
Sina Schader, DrMed • EU and UK QPPV
AbbVie, Germany -
Susanne Ausborn, PhD • Global Head International Regulatory Policy
Roche, Switzerland -
Rodrigo Palacios, MBA • Regulatory Policy Lead
F. Hoffmann-La Roche, Switzerland -
Ronnie Harprit Mundair • Regional Labelling Head - AfME, Canada and LATAM - Senior Director
Pfizer, United Kingdom -
Edith Frénoy, MA, MSc • Director, European Public Policy – Strategic EU Advocacy Lead
MSD Europe Inc., Belgium -
Wija Oortwijn, PhD, MSc • Senior Scientific Researcher, Department for Health Evidence
Radboud University Medical Centre, Netherlands -
Aleksandar Ruzicic • Healthcare Consultants
Executive Insight AG, Switzerland -
Youness Ameur • Regulatory Associate Program Director
Roche, Switzerland -
Jelena Duza • Junior Public Affairs Manager
Novartis, Switzerland -
Elena Popa, MPharm • Regulatory Policy and Innovation Lead
Bayer, Switzerland -
Theo Favard • Vice President of External Relations
European Pharmaceutical Students' Association (EPSA), Belgium -
Francisca Vaz • Senior Specialist, QA Release Coordinator,
Moderna, Switzerland
